Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.
about
Lipid-lowering efficacy of rosuvastatinDoes combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship.Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentEffects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA.High density lipoprotein and cardiovascular diseases.Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
P2860
Q24187891-347EEFB1-E953-44DB-8139-766504FFEF58Q33776187-50998F36-3BE8-4CAC-B0D2-0CB4D9739956Q33814212-BCCA2BF7-2439-4027-A2A6-E92EFFF13A1CQ33930299-D59339FD-11DE-46A1-9417-E2812B70D308Q35029623-D63D414C-7A40-45CA-B085-518A1F6EE972Q35129072-B112CFA0-A724-4BEB-9A67-55428EB0365EQ37041300-DF9DC7DA-8D27-4EB6-AA28-9FF8082BA694Q37043222-D93443CE-23B6-419F-90C9-DDFAB0432DF5Q37695401-582D7134-833F-4A14-B80C-7133B7AFFC8DQ43948677-E5714262-652E-4325-878F-491B6E7886D2Q48209248-73DADF37-2665-468A-8960-9AC77B5FE417Q54518829-A5F92C9A-0385-467D-A920-3F5F38C9216C
P2860
Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Dose-dependent effect of rosuv ...... s with primary hyperlipidemia.
@en
Dose-dependent effect of rosuv ...... s with primary hyperlipidemia.
@nl
type
label
Dose-dependent effect of rosuv ...... s with primary hyperlipidemia.
@en
Dose-dependent effect of rosuv ...... s with primary hyperlipidemia.
@nl
prefLabel
Dose-dependent effect of rosuv ...... s with primary hyperlipidemia.
@en
Dose-dependent effect of rosuv ...... s with primary hyperlipidemia.
@nl
P2093
P2860
P50
P356
P1476
Dose-dependent effect of rosuv ...... ts with primary hyperlipidemia
@en
P2093
Alexandros D Tselepis
Eleni T Bairaktari
Haralampos J Milionis
Leonidas G Christogiannis
P2860
P356
10.1177/1074248408331031
P577
2009-03-01T00:00:00Z